Short Interest in Appili Therapeutics Inc. (OTCMKTS:APLIF) Declines By 69.9%

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 37,400 shares, a decrease of 69.9% from the March 31st total of 124,200 shares. Based on an average daily volume of 1,614,600 shares, the short-interest ratio is presently 0.0 days.

Appili Therapeutics Price Performance

Shares of APLIF stock opened at $0.03 on Friday. Appili Therapeutics has a one year low of $0.02 and a one year high of $0.08. The company has a market capitalization of $3.38 million, a P/E ratio of -0.70 and a beta of -0.30. The company’s 50-day simple moving average is $0.03 and its two-hundred day simple moving average is $0.02.

Appili Therapeutics (OTCMKTS:APLIF) last posted its earnings results on Tuesday, February 13th. The company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). The firm had revenue of $0.36 million for the quarter. On average, research analysts expect that Appili Therapeutics will post -0.04 EPS for the current fiscal year.

About Appili Therapeutics

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.